Arias Cesar A, Singh Kavindra V, Panesso Diana, Murray Barbara E
University of Texas Medical School, Houston, TX 77030, USA.
Antimicrob Agents Chemother. 2007 Jun;51(6):2043-7. doi: 10.1128/AAC.00131-07. Epub 2007 Apr 16.
Ceftobiprole (BAL9141) is an investigational cephalosporin with broad in vitro activity against gram-positive cocci, including enterococci. Ceftobiprole MICs were determined for 93 isolates of Enterococcus faecalis (including 16 beta-lactamase [Bla] producers and 17 vancomycin-resistant isolates) by an agar dilution method following the Clinical and Laboratory Standards Institute recommendations. Ceftobiprole MICs were also determined with a high inoculum concentration (10(7) CFU/ml) for a subset of five Bla producers belonging to different previously characterized clones by a broth dilution method. Time-kill and synergism studies (with either streptomycin or gentamicin) were performed with two beta-lactamase-producing isolates (TX0630 and TX5070) and two vancomycin-resistant isolates (TX2484 [VanB] and TX2784 [VanA]). The MICs of ceftobiprole for 50 and 90% of the isolates tested were 0.25 and 1 microg/ml, respectively. All Bla producers and vancomycin-resistant isolates were inhibited by concentrations of </=1 and </=4 microg/ml, respectively, at the standard inoculum concentration. Ceftobiprole MICs at a high inoculum concentration for a subset of five Bla(+) E. faecalis isolates were </=1 microg/ml. Bactericidal activity was observed against four isolates tested at concentrations as low as 1 microg/ml regardless of the production of beta-lactamase or vancomycin resistance. A combination of ceftobiprole (0.5 microg/ml) and streptomycin (25 microg/ml) was synergistic against Bla(+) TX0630 and TX5070. Ceftobiprole (0.5 microg/ml) plus gentamicin (10 microg/ml) was synergistic against VanB isolate TX2484 and showed enhanced killing, but not synergism, against TX2784 (VanA), despite the absence of high-level resistance to gentamicin. In conclusion, ceftobiprole exhibited good in vitro activity against E. faecalis, including Bla(+) and vancomycin-resistant strains, and exhibited synergism with aminoglycosides against selected isolates.
头孢比普(BAL9141)是一种处于研究阶段的头孢菌素,对革兰氏阳性球菌具有广泛的体外活性,包括肠球菌。按照临床和实验室标准协会的建议,采用琼脂稀释法对93株粪肠球菌(包括16株β-内酰胺酶[Bla]产生菌和17株耐万古霉素菌株)测定了头孢比普的最低抑菌浓度(MIC)。还通过肉汤稀释法对属于不同先前已鉴定克隆的5株Bla产生菌的一个子集,在高接种浓度(10⁷CFU/ml)下测定了头孢比普的MIC。对两株产β-内酰胺酶菌株(TX0630和TX5070)以及两株耐万古霉素菌株(TX2484[VanB]和TX2784[VanA])进行了时间杀菌和协同作用研究(与链霉素或庆大霉素联合)。头孢比普对50%和90%受试菌株的MIC分别为0.25和1μg/ml。在标准接种浓度下,所有Bla产生菌和耐万古霉素菌株分别被≤1和≤4μg/ml的浓度所抑制。对5株Bla(+)粪肠球菌菌株的一个子集在高接种浓度下的头孢比普MIC≤1μg/ml。无论是否产生β-内酰胺酶或耐万古霉素,在低至1μg/ml的浓度下对4株受试菌株均观察到杀菌活性。头孢比普(0.5μg/ml)与链霉素(25μg/ml)联合对Bla(+)的TX0630和TX5070具有协同作用。头孢比普(0.5μg/ml)加庆大霉素(10μg/ml)对VanB菌株TX2484具有协同作用,对TX2784(VanA)显示出增强的杀菌作用,但无协同作用,尽管对庆大霉素不存在高水平耐药。总之,头孢比普对粪肠球菌,包括Bla(+)和耐万古霉素菌株,表现出良好的体外活性,并与氨基糖苷类药物对选定菌株表现出协同作用。